Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should KnowZacks Investment Research • 01/29/22
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3BBusiness Wire • 01/28/22
Bristol Myers Squibb Looks Strong In 2022, Century Deal Can Help Establish Cell Therapy LeadershipSeeking Alpha • 01/17/22
Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain MomentumBenzinga • 01/11/22
Bristol Myers Squibb (BMY) Recently Broke Out Above the 200-Day Moving AverageZacks Investment Research • 01/11/22
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid TumorsPRNewsWire • 01/10/22
Bristol Myers Squibb Shares Jump After J.P. Morgan Healthcare Conference PresentationBenzinga • 01/10/22
Bristol Myers Squibb (BMY) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 01/10/22
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell TherapiesBenzinga • 01/10/22